Anti-Diabetes Drugs - China

China

In 2024, the projected revenue in the Anti-Diabetes Drugs market in China is estimated to reach €8.78bn.
Furthermore, it is expected that this revenue will experience an annual growth rate (CAGR 2024-2029) of 8.07%.
As a result, the market volume is projected to reach €12.94bn by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue in the market, amounting to €35,090.00m in 2024.
China is experiencing a surge in demand for innovative anti-diabetes drugs due to its growing diabetic population and increased healthcare spending.

Key regions: India, Australia, Italy, Europe, Brazil

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

Anti-Diabetes Drugs market has been one of the fastest-growing pharmaceutical markets in China.

Customer preferences: The increasing prevalence of diabetes in China has led to a significant rise in demand for anti-diabetes drugs. The Chinese population is aging rapidly, and unhealthy lifestyles have contributed to the high incidence of diabetes in the country. Additionally, the growing awareness of diabetes and its complications has led to an increased demand for anti-diabetes drugs.

Trends in the market: The anti-diabetes drugs market in China is primarily driven by the increasing prevalence of diabetes in the country. The market is dominated by big multinational pharmaceutical companies, which account for a significant share of the market. The market for anti-diabetes drugs in China is expected to grow at a steady pace in the coming years, driven by the increasing incidence of diabetes and the growing demand for effective and affordable drugs.

Local special circumstances: China has a unique healthcare system, which is heavily influenced by the government. The government plays a significant role in regulating the pharmaceutical industry, including the pricing of drugs. The government's focus on providing affordable healthcare to its citizens has led to the implementation of price controls on drugs, which has impacted the profitability of pharmaceutical companies operating in the country.

Underlying macroeconomic factors: The Chinese economy has been growing at a steady pace, which has led to an increase in the disposable income of the population. This has contributed to the growing demand for healthcare services, including anti-diabetes drugs. The Chinese government has also been investing heavily in the healthcare sector, which has led to the expansion of healthcare facilities and the improvement of the healthcare infrastructure in the country. These factors are expected to drive the growth of the anti-diabetes drugs market in China in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.